









市场行情
/
股票
/
nasdaq-autl
/

Autolus Therapeutics PLC

AUTL

1.640USD

-0.090-5.20%

收盘 12/23, 16:00（美东）报价延迟15分钟

436.47M总市值

亏损市盈率 TTM



Autolus Therapeutics PLC

1.640

-0.090-5.20%

概览公司财务分析

概览

公司

财务

分析

关于 Autolus Therapeutics PLC 公司

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Autolus Therapeutics PLC简介



公司代码AUTL

公司名称Autolus Therapeutics PLC

上市日期Jun 22, 2018

CEOItin (Christian Martin)

员工数量647

证券类型Depository Receipt

年结日Jun 22

公司地址The Mediaworks

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编W12 7FP

电话442038296230

网址https://www.autolus.com/

公司代码AUTL

上市日期Jun 22, 2018

CEOItin (Christian Martin)

Autolus Therapeutics PLC公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Cynthia M. Butitta

Non-Executive Independent Director

10.00K

Mr. Brent Rice

Senior Vice President, Chief Commercial Officer

9.40K

Mr. Christopher Vann

Chief Operating Officer, Senior Vice President

Mr. Robert (Rob) Dolski

Chief Financial Officer, Senior Vice President

Dr. Christian Martin Itin, Ph.D.

Chief Executive Officer, Executive Director

Mr. Michael W. (Mike) Bonney

Chairman of the Board

Mr. John Edward Berriman

Non-Executive Independent Director

Mr. William D. (Bill) Young, Ph.D.

Non-Executive Independent Director

Mr. David Brochu

Senior Vice President, Chief Technical Officer

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Cynthia M. Butitta

Non-Executive Independent Director

10.00K

Mr. Brent Rice

Senior Vice President, Chief Commercial Officer

9.40K

Mr. Christopher Vann

Chief Operating Officer, Senior Vice President

Mr. Robert (Rob) Dolski

Chief Financial Officer, Senior Vice President

Dr. Christian Martin Itin, Ph.D.

Chief Executive Officer, Executive Director

Mr. Michael W. (Mike) Bonney

Chairman of the Board

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

20.92M

100.00%

United Kingdom

0.00

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月2日周二

持股股东

股东类型

持股股东

占比

Syncona Investment Management Limited

11.55%

MAK Capital One, LLC

10.10%

Clarus Ventures, LLC

7.70%

Syncona Portfolio Ltd

6.25%

Armistice Capital LLC

5.86%

其他

58.54%

持股股东

占比

Syncona Investment Management Limited

11.55%

MAK Capital One, LLC

10.10%

Clarus Ventures, LLC

7.70%

Syncona Portfolio Ltd

6.25%

Armistice Capital LLC

5.86%

其他

58.54%

股东类型

持股股东

占比

Hedge Fund

23.57%

Investment Advisor

23.48%

Corporation

12.52%

Investment Advisor/Hedge Fund

9.14%

Venture Capital

8.06%

Sovereign Wealth Fund

5.64%

Holding Company

5.55%

Research Firm

1.83%

Private Equity

1.74%

其他

8.47%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

230

194.47M

90.55%

+128.60K

2025Q3

237

202.34M

94.14%

-20.86M

2025Q2

235

223.88M

91.00%

-2.80M

2025Q1

228

230.12M

90.84%

-11.63M

2024Q4

235

229.60M

92.37%

-10.27M

2024Q3

225

234.01M

89.22%

+30.38M

2024Q2

227

202.70M

79.95%

+2.45M

2024Q1

217

200.05M

58.18%

+45.35M

2023Q4

191

140.21M

76.10%

+4.14M

2023Q3

169

139.76M

70.07%

+377.17K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Syncona Investment Management Limited

30.73M

11.55%

+30.73M

Sep 30, 2024

MAK Capital One, LLC

16.96M

6.37%

+16.96M

Jun 30, 2025

Clarus Ventures, LLC

20.49M

7.7%

Jun 30, 2025

Syncona Portfolio Ltd

16.64M

6.25%

Jun 30, 2025

Armistice Capital LLC

12.00M

4.51%

+1.00M

+9.09%

Jun 30, 2025

Qatar Investment Authority

15.00M

5.64%

Mar 01, 2025

PPF Group N.V.

14.78M

5.55%

+170.00K

+1.16%

Oct 24, 2024

Polygon Management Ltd.

9.50M

3.57%

+900.00K

+10.47%

Jun 30, 2025

Schroder Investment Management Ltd. (SIM)

3.61M

1.36%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.56%

Virtus LifeSci Biotech Clinical Trials ETF

0.49%

ALPS Medical Breakthroughs ETF

0.17%

iShares Health Innovation Active ETF

0.07%

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

iShares Biotechnology ETF

0.02%

SPDR S&P International Small Cap ETF

0.01%

Tema Oncology ETF

Fidelity Fundamental Small-Mid Cap ETF

Invesco NASDAQ Future Gen 200 ETF

占比0.56%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.49%

ALPS Medical Breakthroughs ETF

占比0.17%

iShares Health Innovation Active ETF

占比0.07%

ProShares Ultra Nasdaq Biotechnology

占比0.03%

Invesco Nasdaq Biotechnology ETF

占比0.03%

iShares Biotechnology ETF

占比0.02%

SPDR S&P International Small Cap ETF

占比0.01%

Tema Oncology ETF

占比0%

Fidelity Fundamental Small-Mid Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Autolus Therapeutics PLC的前五大股东是谁？



Autolus Therapeutics PLC 的前五大股东如下：
Syncona Investment Management Limited持有股份：30.73M，占总股份比例：11.55%。
MAK Capital One, LLC持有股份：16.96M，占总股份比例：6.37%。
Clarus Ventures, LLC持有股份：20.49M，占总股份比例：7.70%。
Syncona Portfolio Ltd持有股份：16.64M，占总股份比例：6.25%。
Armistice Capital LLC持有股份：12.00M，占总股份比例：4.51%。